Nov-Dec 2011
HOTEL LALIT ASHOK,
22nd OCTOBER,
BANGALORE, INDIA
PHARMALEADERS ACADEMY
To review the current and future conditions for, and barriers to, a dynamic, productive and sustainable relationship between the Pharmaleaders, academic medicine and the pharmaceutical industry – the purpose of which is to discover and deliver safe, effective and affordable new medicines to patients based on need.To identify policies that would promote such a relationship.
Tasks
To obtain evidence about the current and future prospects for the pharmaceutical industry. To obtain evidence about the contribution doctors can make to a successful alliance between the pharmaceutical industry and medicine. To obtain evidence of successes and failures in the relationship between the Pharmaleaders, academic medicine and the pharmaceutical industry
The Academy
Leaders of The Pharmaceutical Industry, Lifesciences, Biotech, Government & Academia.
Membership
To become the members of the Pharmaleaders Academy, one must be the owner of the firm & Annual membership fees of Rs 1,00,000/-(INR)
Malvinder to Pharmaleaders
“India's Is Listed As The Largest Hospital Chain In Asia. To me Parkway is only the first step in Fortis' global expansion. We are talking about a market capitalization in excess of $5 billion and profits which are significantly up” ..read more..
Dr. Surinder singh to Pharmaleaders
Imagine administering a paracetamol tablet to a near and dear one who is down with fever only to find that the medicine is having no effect. This scenario sounds scary, but it could be actually be happening ..... ..read more..
Tapan Ray to Pharmaleaders
“Government, Corporates and the civil society in general must contribute according to their respective abilities, obligations and enlightened societal interests, towards this direction.” ..read more..
Kiran Majumdar Shaw to Pharmaleaders
“The MSCC, which has the active support of India's well known woman entrepreneur and Biocon founder Kiran Mazumdar-Shaw, has been set up to bring about a discernable change in the treatment and .......... ” ..read more..
Dr Kamal Sharma to Pharmaleaders
“I am still spending some time to study the details of the bill. However, my first reaction is that there is nothing major for the generic industry as far as the bid is concerned, except for the fact that there is certainly going ..........” ..read more..